Urapidil and Esmolol
PreclinicalSmall molecule
Urapidil and Esmolol is one of 24 small molecule programs targeting Intracerebral Hemorrhage. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
23
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Intracerebral Hemorrhage
#DrugCompanyPhaseTrials
1Depakote
AbbVieApproved
Lovenox
SanofiApproved
Myrbetriq
AstellasApproved
Cyklokapron
JJ Molner
Approved
Normodyne
AAlvogen Korea
Approved
Olumiant
Eli LillyPhase 2
Minocycline /d
UUniversity of Florida
Phase 3
Celebrex
PPhiladelphia Eye Associates
Phase 2
Recombinant Factor Viia
SSheba Medical Center
Phase 3
PPA Intervention
SSecond Affiliated Hospital, School of Medicine, Zhejiang University
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Urapidil and Esmolol. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- QQianfoshan Hospital